Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company’s current programs center on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for indications that include neurofibromatosis type 1-associated plexiform neurofibromas and selected oncology uses. Pasithea Therapeutics Corp. also works on additional therapeutic candidates aimed at neurological and psychiatric conditions, reflecting a broader emphasis on diseases with significant unmet medical need. The company operates through therapeutic development activities and clinic-related services, positioning itself across both drug research and patient-facing healthcare applications. Based in Miami Beach, Florida, Pasithea Therapeutics Corp. plays a role in the clinical-stage biotechnology market by advancing targeted treatment candidates for complex disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Tiago Reis Marques M.D., Ph.D.

Employees

5

Headquarters

Miami Beach, FL, United States

Website

www.pasithea.com